Integrated PET/MR Assessment of Brain Recovery After Recanalization of Non-Acute Atherosclerotic MCA Occlusion
NCT07927569, Recruiting, Qianfoshan Hospital
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Integrated PET/MR Assessment of Brain Recovery After Recanalization of Non-Acute Atherosclerotic MCA Occlusion | ClinicalTrials.gov |
| NCT number | NCT07927569 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 15 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Qianfoshan Hospital | ClinicalTrials.gov |
| Conditions | Middle Cerebral Artery Occlusion, Intracranial Atherosclerosis, Cerebrovascular Disease | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Perfusion-Metabolism Abnormality Burden in the Affected Hemisphere From Baseline to 1 Month After Recanalization (ΔPMB) | Baseline and 1 Month After Recanalization; | The cerebral perfusion-metabolism coupling index will be derived from spatially corresponding cerebral perfusion and PET-based metabolic measurements within prespecified regions of interest in the affected MCA territory. The exact coupling metric, its calculation, normalization, and interpretation will be defined in the prespecified imaging analysis protocol. The primary measure will be the within-participant change in this index between baseline and the specified follow-up visit. | ClinicalTrials.gov |
| Secondary | Change in Regional Cerebral Blood Flow From Baseline to 1 Month After Recanalization; | Preoperative baseline and 1 month after recanalization. | Cerebral blood flow (CBF) in the affected hemisphere will be quantified using arterial spin labeling (ASL) MRI, expressed in mL/100 g/min. The change in CBF will be calculated as the value at 1 month after recanalization minus the preoperative baseline value. | ClinicalTrials.gov |
| Secondary | Change in Arterial Cerebral Blood Volume in the Affected Hemisphere | Baseline and 1 Month After Recanalization; | Arterial cerebral blood volume (aCBV) in the affected hemisphere will be quantified using the prespecified ASL-derived imaging method. The change in aCBV will be calculated as the value at 1 month after recanalization minus the preoperative baseline value. | ClinicalTrials.gov |
| Secondary | Change in Arterial Transit Time in the Affected Hemisphere | Baseline and 1 Month After Recanalization; | Arterial transit time (ATT) will be quantified using the prespecified ASL MRI technique and expressed in milliseconds. The change in ATT will be calculated as the value at 1 month after recanalization minus the preoperative baseline value. | ClinicalTrials.gov |
| Secondary | Change in 18F-FDG Standardized Uptake Value Ratio in the Affected Hemisphere | Baseline and 1 Month After Recanalization; | Cerebral glucose metabolism will be assessed using 18F-fluorodeoxyglucose (18F-FDG) PET. The standardized uptake value ratio (SUVR) will be calculated using the prespecified reference region and expressed as a dimensionless ratio. The change in SUVR will be calculated as the value at 1 month after recanalization minus the preoperative baseline value. | ClinicalTrials.gov |
| Secondary | Change in Hemispheric Asymmetry Index of Cerebral Blood Flow | Baseline and 1 Month After Recanalization; | The hemispheric asymmetry index of cerebral blood flow (CBF-AI) will be calculated from corresponding CBF measurements in the affected and contralateral hemispheres using the prespecified asymmetry formula. The change will be calculated as the index at 1 month after recanalization minus the baseline index. | ClinicalTrials.gov |
| Secondary | Change in Hemispheric Asymmetry Index of Arterial Cerebral Blood Volume | Baseline and 1 Month After Recanalization; | The hemispheric asymmetry index of arterial cerebral blood volume (aCBV-AI) will be derived from aCBV measurements in the affected and contralateral hemispheres using the prespecified asymmetry formula. The change will be calculated as the index at 1 month after recanalization minus the baseline index. | ClinicalTrials.gov |
| Secondary | Change in Hemispheric Asymmetry Index of Arterial Transit Time | Baseline and 1 Month After Recanalization; | The hemispheric asymmetry index of arterial transit time (ATT-AI) will be calculated from ATT measurements in the affected and contralateral hemispheres using the prespecified asymmetry formula. The change will be calculated as the index at 1 month after recanalization minus the baseline index. | ClinicalTrials.gov |
| Secondary | Change in Hemispheric Asymmetry Index of 18F-FDG Standardized Uptake Value Ratio | Baseline and 1 Month After Recanalization; | Change in Hemispheric Asymmetry Index of 18F-FDG Standardized Uptake Value Ratio | ClinicalTrials.gov |
| Secondary | Proportion of Brain Regions Showing Spatially Concordant Perfusion and Metabolic Improvement After Recanalization | Baseline and 1 Month After Recanalization; | Integrated PET/MR will be used to identify regions of interest (ROIs) exhibiting both perfusion improvement and metabolic improvement at 1 month after recanalization compared with preoperative baseline. Spatial coupling will be quantified as the percentage of evaluable ROIs demonstrating concordant improvement in both parameters, according to prespecified quantitative thresholds and spatial matching criteria. | ClinicalTrials.gov |
| Secondary | Change in Global Efficiency of Resting-State Functional Brain Networks | Baseline and 1 Month After Recanalization; | Resting-state functional MRI will be used to construct whole-brain functional connectivity networks. Global efficiency will be calculated using graph-theoretical analysis as a quantitative measure of network-wide information integration. The change in global efficiency will be calculated as the value at 1 month after recanalization minus the preoperative baseline value. | ClinicalTrials.gov |
| Secondary | Change in Interhemispheric Functional Connectivity Strength | Baseline and 1 Month After Recanalization; | Interhemispheric functional connectivity will be assessed using resting-state blood oxygen level-dependent (BOLD) MRI. Connectivity strength between prespecified corresponding regions in the two hemispheres will be quantified using Fisher z-transformed correlation coefficients. The change will be calculated as the value at 1 month after recanalization minus the preoperative baseline value. | ClinicalTrials.gov |
| Secondary | Change in Nodal Efficiency of Prespecified Brain Network Hubs | Preoperative baseline and 1 month after recanalization. | Nodal efficiency of prespecified key brain regions will be calculated from resting-state functional connectivity networks using graph-theoretical analysis. Changes in nodal efficiency will be evaluated by comparing measurements obtained before recanalization and at 1 month after recanalization. The regions of interest and the summary metric will be defined in the prespecified imaging analysis protocol. | ClinicalTrials.gov |
| Secondary | Correlation Between 1-Month Change in Perfusion-Metabolism Abnormality Burden and Modified Rankin Scale Score at 90 Days | Preoperative baseline and 1 month after recanalization. | The association between the change in perfusion-metabolism abnormality burden (ΔPMB) from baseline to 1 month after recanalization and functional disability at 90 days will be assessed. Functional disability will be measured using the modified Rankin Scale (mRS), ranging from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability. The association will be quantified using a prespecified correlation coefficient. | ClinicalTrials.gov |
| Secondary | Correlation Between 1-Month Change in Perfusion-Metabolism Abnormality Burden and Barthel Index Score at 90 Days | Preoperative baseline, 1 month after recanalization (ΔPMB), and 90 days after recanalization (Barthel Index). | The association between ΔPMB from baseline to 1 month after recanalization and activities of daily living at 90 days will be assessed. Functional independence will be measured using the Barthel Index (BI), ranging from 0 to 100, with higher scores indicating greater independence in activities of daily living. The association will be quantified using a prespecified correlation coefficient. | ClinicalTrials.gov |
| Secondary | Correlation Between 1-Month Change in Perfusion-Metabolism Abnormality Burden and EQ-5D Health Utility Index at 90 Days | Preoperative baseline, 1 month after recanalization (ΔPMB), and 90 days after recanalization (EQ-5D). | The association between ΔPMB from baseline to 1 month after recanalization and health-related quality of life at 90 days will be assessed using the EuroQol 5-Dimension (EQ-5D) questionnaire. EQ-5D responses will be converted into a health utility index using the prespecified instrument version and population-specific value set. Higher utility scores generally indicate better health-related quality of life. The association will be quantified using a prespecified correlation coefficient. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)